ISSN 2149-2263 | E-ISSN 2149-2271
pdf
Aspirin resistance: Where are we now? [Anatol J Cardiol]
Anatol J Cardiol. 2013; 13(4): 370-373 | DOI: 10.5152/akd.2013.107

Aspirin resistance: Where are we now?

Okay Abacı1, Kadriye Orta Kılıçkesmez1
Department of Cardiology, Cardiology Institute of Istanbul University, İstanbul-Turkey

Aspirin is an effective antiplatelet drug for preventing thrombo-embolic vascular events. However, clinical and laboratory evidence demonstrates diminished or no response to aspirin in some patients that is called aspirin resistance. This situation has been reported to be independently associated with an increased risk of adverse cardiovascular events. The exact mechanism of aspirin resistance has not been established yet. The clinical, pharmacological and genetic factors may be associated with aspirin resistance. However, there is not currently standardized test to the diagnosis and no proven effective treatment of aspirin resistance. This article summarizes aspirin resistance, discussing its definition, clinical outcomes, laboratory tests, possible causes and therapeutic approaches.

Keywords: Aspirin resistance, clinical outcomes, laboratory tests, therapeutic approaches

Okay Abacı, Kadriye Orta Kılıçkesmez. Aspirin resistance: Where are we now?. Anatol J Cardiol. 2013; 13(4): 370-373
Manuscript Language: English


Journal Metrics

Journal Citation Indicator: 0.18
CiteScore: 1.1
Source Normalized Impact
per Paper:
0.22
SCImago Journal Rank: 0.348

Quick Search

Copyright © 2024 The Anatolian Journal of Cardiology



Kare Publishing is a subsidiary of Kare Media.